Answers are grounded in this paper and cite their sources.
Gastric cancer remains one of the most frequent malignant pathology worldwide.It is currently the fourth most common cancer found worldwide and the second leading cause of death by cancer.In 2020 over 1 milion new cases of GC were diagnosed, most of them were advanced which leads to a poor prognosis.Despite the great progress in the treatment of gastric cancer there are still critical needs to address.Due to the progress made in the molecular study of gastric cancer several targeted therapies have been developed to treat unresectable or metastatic gastric cancer.To date, there are three established biomarkers with good responses to targeted therapy: HER-2 (human epidermal growth factor receptor-2) positive for trastuzumab and trastuzumab deruxtecan, overexpression of PD-L1 for nivolumab, MSI-H (microsatellite instability high) for pembrolizumab.As new biomarkers shows up possibly there will be more treatment options for those patients with advanced/mGC.Promising results are seen in the most recent studied biomarkers Claudin18.2and FGFR2b in this specific population.This review will sumarize the role of biomarkers, diagnostic methods and the advantage of molecular targeted therapy in advanced/mGC.
No takes yet. Share an insight, caveat, or question.
Baciu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: